 Kazia Therapeutics Ltd NASDAQ: KZIA has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd to develop and commercialize Kazias investigational new drug, paxalisib, in Greater China. Kazia retains rights to the development and commercialization of paxalisib in all other territories and will continue to drive forward the GBM AGILE pivotal study as planned, including in China. 